TAVR-Talks Part II! Where does Abbott see opportunity? How does Medtronic view competition?

In this week’s episode, we follow up on our first episode focused on Transcatheter Aortic Valve Replacement (TAVR). This time we speak with one of the market leaders, Medtronic, about their broad structural heart portfolio. Nina Goodheart, president of Structural Heart, walks us through each valve and explains why Medtronic is sponsoring a clinical trial pitting its aortic valve against a rival’s. We also hear from the new competitor on the block, Abbott, which recently earned FDA approval for its valve. Santosh Prabhu, PhD, introduces the new entry and explains why this work is so important to him personally.